Genstruct Inc has signed an agreement recently with Pfizer to collaborate on a variety of research projects to help better understand complex diseases. This deal is part of a continuing, multi-year relationship Genstruct has developed with Pfizer. Terms of the partnership are not being disclosed.

This new arrangement will include research projects with several Pfizer units, including Worldwide Safety Sciences, the Proteomics Global Centre of Excellence, and Clinical Sciences. Genstruct will use its Molecular Epistemics Platform to generate hypotheses to reveal underlying mechanisms of action and toxicity to help Pfizer prioritize and develop new medicines for treating complex diseases, Genstruct said in a release.

"We are pleased to be growing our relationship with Pfizer," Keith O. Elliston, president and CEO of Genstruct said adding, "We have developed a novel approach to mechanism discovery and this agreement with the world's premier pharmaceutical research and development organization should provide additional validation of our Molecular Epistemics Platform. Through this relationship, we will work with Pfizer scientists to identify mechanisms and biomarkers to improve leads and optimize clinical trial design and execution."

Genstruct is a knowledge-driven discovery company focused on pioneering new approaches to the understanding and treatment of complex diseases in the areas of oncology, metabolic disorders, and inflammation.